Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.48 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 4/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13500330 | 0.89 | NTRK1 (0.51) | TRPV1NTRK1NAMPTPTGESEPHX2 | |
| SCHEMBL3579748 | 0.85 | ALOX5 (0.50) | TRPV1NTRK1NAMPTPTGESCNR1 | |
| SCHEMBL13500273 | 0.84 | NPC1 (0.51) | NAMPTPIK3CBCNR1 | |
| SCHEMBL13500332 | 0.82 | MAPK1 (0.56) | NAMPTPIK3CB | |
| SCHEMBL3666096 | 0.78 | LCK (0.54) | TRPV1NTRK1NAMPTEPHX2 | |
| SCHEMBL13500282 | 0.77 | SCN2A (0.55) | NAMPTPIK3CBHDAC6 | |
| SCHEMBL14433931 | 0.74 | CNR1 (0.55) | TRPV1NTRK1NAMPTPTGESCNR1 | |
| SCHEMBL1792584 | 0.69 | CA1 (0.65) | TRPV1NAMPTABL1 | |
| SCHEMBL3576068 | 0.69 | NPC1 (0.48) | NAMPT | |
| SCHEMBL1789121 | 0.69 | CA1 (0.56) | TRPV1NAMPTABL1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048543-A1 | PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY | TEK, TYMP, TIE1 | TRPV1 4307/4885NTRK1 2866/4885NAMPT 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.